Krüger, Ullrich

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Experimental Dermatology"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Anders, N."],["dc.contributor.author","Konig, I. R."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Schmidt, D."],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Ziegler, Andreas"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Volkenandt, Matthias"],["dc.contributor.author","Kaiser, R."],["dc.contributor.author","Westphal, G."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:12:01Z"],["dc.date.available","2018-11-07T10:12:01Z"],["dc.date.issued","2006"],["dc.format.extent","198"],["dc.identifier.isi","000235370600041"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40158"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.publisher.place","Oxford"],["dc.relation.conference","33rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF)"],["dc.relation.eventlocation","Aachen, GERMANY"],["dc.relation.issn","0906-6705"],["dc.title","Variations of the MC1R and the GSTM1 and T1 genes in cutaneous malignant melanoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","576"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Investigative Dermatology"],["dc.bibliographiccitation.lastpage","582"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Schulz, U."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Schinner, S."],["dc.contributor.author","Fuzesi, Laszlo"],["dc.contributor.author","Neumann, C."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:06:19Z"],["dc.date.available","2018-11-07T10:06:19Z"],["dc.date.issued","2002"],["dc.description.abstract","Peroxisome proliferator-activated receptor gamma is a member of the nuclear receptor superfamily involved in adipocyte differentiation and glucose homeostasis. There is evidence that peroxisome proliferator-activated receptor gamma may also act as a tumor suppressor. Here, we demonstrate expression of peroxisome proliferator-activated receptor gamma in benign melanocytic naevi, different variants of primary cutaneous melanomas, and melanoma metastases. Peroxisome proliferator-activated receptor gamma protein and peroxisome proliferator-activated receptor gamma1 mRNA were also detected in human melanoma cell lines. The peroxisome proliferator-activated receptor gamma specific agonists 15-deoxy-Delta(12,14)-prostaglandin J(2), troglitazone, and rosiglitazone dose-dependently inhibited cell proliferation in four melanoma cell lines, whereas a specific agonist of peroxisome proliferator-activated receptor alpha had no such effect. At a concentration of 50 muM rosiglitazone, the most potent peroxisome proliferator-activated receptor gamma agonist tested suppressed cell growth by approximately 90%. Apoptosis could be induced in melanoma cell lines by incubation with tumor-necrosis-factor-related apoptosis-inducing ligand. In contrast, the growth inhibitory effect of peroxisome proliferator-activated receptor gamma activation was independent of apoptosis and seemed to occur primarily through induction of cell cycle arrest. Our data indicate that melanoma cell growth may be modulated through peroxisome proliferator-activated receptor gamma."],["dc.identifier.doi","10.1046/j.1523-1747.2002.01861.x"],["dc.identifier.isi","000177951400006"],["dc.identifier.pmid","12230498"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39070"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.relation.issn","0022-202X"],["dc.title","Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Investigative Dermatology"],["dc.bibliographiccitation.volume","125"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Wussow, M."],["dc.contributor.author","Schmidt, D."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:56:17Z"],["dc.date.available","2018-11-07T10:56:17Z"],["dc.date.issued","2005"],["dc.format.extent","A58"],["dc.identifier.isi","000231862600339"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49977"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.publisher.place","Oxford"],["dc.relation.conference","35th Annual Meeting of the European-Society-for-Dermatological-Research"],["dc.relation.eventlocation","Tubingen, GERMANY"],["dc.relation.issn","0022-202X"],["dc.title","Evidence for a PPARgamma agonist-induced proteasomal degradation of cyclin D1 in melanoma cell lines"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","5"],["dc.bibliographiccitation.volume","296"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Kaiser, R."],["dc.contributor.author","Matern, P."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Westphal, Goetz Alexander"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Ziegler, Andreas"],["dc.contributor.author","Neumann, C."],["dc.contributor.author","Konig, I. R."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:48:15Z"],["dc.date.available","2018-11-07T10:48:15Z"],["dc.date.issued","2004"],["dc.description.abstract","The three peroxisome proliferator-activated receptor (PPAR) subtypes alpha, delta (beta), and gamma belong to the group of nuclear receptors that act as ligand-activated transcription factors. Recently, expression of PPARalpha and gamma in keratinocytes has been demonstrated, and ligands of PPARalpha and gamma have been found to enhance epidermal maturation and protect against cutaneous inflammation. There is evidence for a possible role of PPARs in psoriasis, as the expression of PPARalpha and gamma is decreased in lesional skin and treatment with PPARgamma agonists improves psoriatic keratinocyte pathology in vitro and in vivo. We performed a case-control study to search for possible associations between variations in the genes encoding PPARalpha and gamma and psoriasis. Seven variations in these genes were analyzed in 192 patients with chronic plaque-type psoriasis and 330 healthy controls by PCR-based methods. No association between any of the investigated PPAR variants and psoriasis was found. Our findings argue against a significant contribution of the investigated PPAR variations to the genetic basis of psoriasis."],["dc.identifier.doi","10.1007/s00403-004-0463-6"],["dc.identifier.isi","000222059400001"],["dc.identifier.pmid","15083308"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48146"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-3696"],["dc.title","Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","71"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Dermatological Science"],["dc.bibliographiccitation.lastpage","73"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Kingo, Kuelli"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Traks, Tanel"],["dc.contributor.author","Raetsep, Ranno"],["dc.contributor.author","Raud, Kristi"],["dc.contributor.author","Reimann, Ene"],["dc.contributor.author","Krueger, Ullrich"],["dc.contributor.author","Silm, Helgi"],["dc.contributor.author","Vasar, Eero"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Koks, Sulev"],["dc.date.accessioned","2018-11-07T08:47:55Z"],["dc.date.available","2018-11-07T08:47:55Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1016/j.jdermsci.2009.10.007"],["dc.identifier.isi","000273667200015"],["dc.identifier.pmid","19926456"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21078"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0923-1811"],["dc.title","Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Investigative Dermatology"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Schulz, U."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Schinner, S."],["dc.contributor.author","Fuzesi, Laszlo"],["dc.contributor.author","Neumann, C."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:06:22Z"],["dc.date.available","2018-11-07T10:06:22Z"],["dc.date.issued","2002"],["dc.format.extent","751"],["dc.identifier.isi","000177951400254"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39081"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.publisher.place","Malden"],["dc.relation.issn","0022-202X"],["dc.title","Agonists of peroxisome proliferator-activated receptor (PPAR) gamma inhibit cell growth in malignant melanoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","282"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Investigative Dermatology"],["dc.bibliographiccitation.lastpage","284"],["dc.bibliographiccitation.volume","124"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Kingo, Kuelli"],["dc.contributor.author","Kleensang, A."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Konig, I. R."],["dc.contributor.author","Silm, Helgi"],["dc.contributor.author","Westphal, Goetz Alexander"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T08:42:05Z"],["dc.date.available","2018-11-07T08:42:05Z"],["dc.date.issued","2005"],["dc.identifier.doi","10.1111/j.0022-202X.2004.23556.x"],["dc.identifier.isi","000225951300048"],["dc.identifier.pmid","15654990"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19625"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.relation.issn","0022-202X"],["dc.title","Association of TNF-238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","443"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","447"],["dc.bibliographiccitation.volume","301"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Stiens, Gerthild"],["dc.contributor.author","Koenig, Inke R."],["dc.contributor.author","Schmidt, Diane"],["dc.contributor.author","Platzer, Anja"],["dc.contributor.author","Krueger, Ullrich"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T08:27:58Z"],["dc.date.available","2018-11-07T08:27:58Z"],["dc.date.issued","2009"],["dc.description.abstract","Serotonin is a monoamine acting as a neuromediator in the central and peripheral nervous system. Recently, serotonin has also been shown to influence T- and B-cell function. The serotonin transporter is central in the regulation of the serotonergic system and widely expressed on cells of the immune system. A functional length polymorphism in the promoter of the serotonin transporter gene (5-HTTLPR) has been implicated in the genetic background of depression. Psoriasis is a complex disease with a polygenetic inheritance. In light of the role of T-cell mediated inflammation in psoriasis and the increased prevalence of depression in psoriatic patients, we analyzed the 5-HTTLPR polymorphism in 309 patients with psoriasis vulgaris and 315 healthy control individuals. No significant differences in genotype distribution and allele frequencies were found. There was also no difference in the score of the Hamilton Rating Scale for Depression in patients with psoriasis (n = 137) characterized by carriage of different 5-HTTLPR genotypes. These findings argue against a major contribution of the 5-HTTLPR polymorphism to psoriasis susceptibility and the occurrence of depressive symptoms among psoriatic patients."],["dc.description.sponsorship","Deutscher Psoriasis Bund"],["dc.identifier.doi","10.1007/s00403-008-0909-3"],["dc.identifier.isi","000267389100005"],["dc.identifier.pmid","18979110"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3521"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16317"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-3696"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Investigative Dermatology"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Zschunke, F."],["dc.contributor.author","Neumann, C."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:46:51Z"],["dc.date.available","2018-11-07T10:46:51Z"],["dc.date.issued","2004"],["dc.identifier.isi","000222483400249"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47836"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.publisher.place","Malden"],["dc.relation.conference","34th Annual Meeting of the European-Society-for-Dermatological-Research"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","0022-202X"],["dc.title","The expression of leukocyte-chemoattractive factors suggest a pathophysiological link between psoriatic skin and bone disease"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","101"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","105"],["dc.bibliographiccitation.volume","300"],["dc.contributor.author","Mössner, Rotraut"],["dc.contributor.author","Thaci, Diamant"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Pätzold, Sylvie"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Krüger, Ullrich"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T11:17:20Z"],["dc.date.available","2018-11-07T11:17:20Z"],["dc.date.issued","2008"],["dc.description.abstract","Infliximab is a monoclonal antibody directed against TNF-alpha. It has been approved for use in rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis and plaque-type psoriasis. In case reports, positive effects on pustular variants of psoriasis have also been reported. However, paradoxically, manifestation of pustular psoriasis and plaque-type psoriasis has been reported in patients treated with TNF antagonists including infliximab for other indications. Here, we report on 5 patients with chronic plaque-type psoriasis who developed palmoplantar pustulosis during or after discontinuation of infliximab therapy. In two of the five cases, manifestation of palmoplantar pustulosis was not accompanied by worsening of plaque-type psoriasis. Possibly, site-specific factors or a differential contribution of immunological processes modulated by TNF inhibitors to palmoplantar pustulosis and plaque-type psoriasis may have played a role."],["dc.identifier.doi","10.1007/s00403-008-0831-8"],["dc.identifier.isi","000253573300001"],["dc.identifier.pmid","18239925"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3520"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54781"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0340-3696"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]